TW201325470A - 含有高量sn-2棕櫚酸酯及果寡糖之嬰兒配方 - Google Patents
含有高量sn-2棕櫚酸酯及果寡糖之嬰兒配方 Download PDFInfo
- Publication number
- TW201325470A TW201325470A TW101141934A TW101141934A TW201325470A TW 201325470 A TW201325470 A TW 201325470A TW 101141934 A TW101141934 A TW 101141934A TW 101141934 A TW101141934 A TW 101141934A TW 201325470 A TW201325470 A TW 201325470A
- Authority
- TW
- Taiwan
- Prior art keywords
- infant formula
- fat
- infant
- palmitic acid
- formula
- Prior art date
Links
- 235000013350 formula milk Nutrition 0.000 title claims abstract description 89
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 title description 16
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims abstract description 77
- 235000021314 Palmitic acid Nutrition 0.000 claims abstract description 33
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims abstract description 33
- 239000000344 soap Substances 0.000 claims abstract description 30
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims abstract description 13
- 229940012843 omega-3 fatty acid Drugs 0.000 claims abstract description 13
- 235000020665 omega-6 fatty acid Nutrition 0.000 claims abstract description 12
- 229940033080 omega-6 fatty acid Drugs 0.000 claims abstract description 12
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims abstract description 10
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 9
- 102000004407 Lactalbumin Human genes 0.000 claims abstract description 9
- 108090000942 Lactalbumin Proteins 0.000 claims abstract description 9
- 239000011575 calcium Substances 0.000 claims abstract description 9
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 9
- 235000021241 α-lactalbumin Nutrition 0.000 claims abstract description 9
- 241000186000 Bifidobacterium Species 0.000 claims abstract description 8
- 210000001072 colon Anatomy 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims description 46
- 235000019197 fats Nutrition 0.000 claims description 35
- 238000009472 formulation Methods 0.000 claims description 31
- 210000003608 fece Anatomy 0.000 claims description 21
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 18
- 235000018102 proteins Nutrition 0.000 claims description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 13
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 13
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 11
- 238000006116 polymerization reaction Methods 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 244000052616 bacterial pathogen Species 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 1
- 235000013399 edible fruits Nutrition 0.000 claims 1
- 235000020256 human milk Nutrition 0.000 abstract description 12
- 210000004251 human milk Anatomy 0.000 abstract description 11
- 150000003626 triacylglycerols Chemical class 0.000 abstract description 10
- 238000000034 method Methods 0.000 abstract description 9
- 150000004665 fatty acids Chemical class 0.000 description 29
- 235000014113 dietary fatty acids Nutrition 0.000 description 27
- 229930195729 fatty acid Natural products 0.000 description 27
- 239000000194 fatty acid Substances 0.000 description 27
- 230000002550 fecal effect Effects 0.000 description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 14
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 11
- 239000007788 liquid Substances 0.000 description 10
- 235000020778 linoleic acid Nutrition 0.000 description 9
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 9
- 150000002632 lipids Chemical class 0.000 description 9
- 235000015112 vegetable and seed oil Nutrition 0.000 description 9
- 239000008158 vegetable oil Substances 0.000 description 9
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 8
- 150000004671 saturated fatty acids Chemical class 0.000 description 7
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 6
- 235000021588 free fatty acids Nutrition 0.000 description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 description 6
- 239000011707 mineral Substances 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 5
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 235000010755 mineral Nutrition 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 5
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 4
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 4
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000005642 Oleic acid Substances 0.000 description 4
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 4
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 229940090949 docosahexaenoic acid Drugs 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 4
- 229920001542 oligosaccharide Polymers 0.000 description 4
- 238000003908 quality control method Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 4
- 125000005457 triglyceride group Chemical group 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- RQFCJASXJCIDSX-UHFFFAOYSA-N 14C-Guanosin-5'-monophosphat Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(O)=O)C(O)C1O RQFCJASXJCIDSX-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- GRSZFWQUAKGDAV-UHFFFAOYSA-N Inosinic acid Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229960004232 linoleic acid Drugs 0.000 description 3
- 229960004488 linolenic acid Drugs 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- 239000006014 omega-3 oil Substances 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 235000003441 saturated fatty acids Nutrition 0.000 description 3
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 2
- 241000024188 Andala Species 0.000 description 2
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000005639 Lauric acid Substances 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 2
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000004130 lipolysis Effects 0.000 description 2
- 230000008376 long-term health Effects 0.000 description 2
- 235000012680 lutein Nutrition 0.000 description 2
- 229960005375 lutein Drugs 0.000 description 2
- 239000001656 lutein Substances 0.000 description 2
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 2
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 2
- 235000010930 zeaxanthin Nutrition 0.000 description 2
- 239000001775 zeaxanthin Substances 0.000 description 2
- 229940043269 zeaxanthin Drugs 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- MJYQFWSXKFLTAY-OVEQLNGDSA-N (2r,3r)-2,3-bis[(4-hydroxy-3-methoxyphenyl)methyl]butane-1,4-diol;(2r,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O.C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 MJYQFWSXKFLTAY-OVEQLNGDSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- OIZGSVFYNBZVIK-FHHHURIISA-N 3'-sialyllactose Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O OIZGSVFYNBZVIK-FHHHURIISA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000014698 Brassica juncea var multisecta Nutrition 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000006008 Brassica napus var napus Nutrition 0.000 description 1
- 235000006618 Brassica rapa subsp oleifera Nutrition 0.000 description 1
- 244000188595 Brassica sinapistrum Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- 241000698776 Duma Species 0.000 description 1
- GRSZFWQUAKGDAV-KQYNXXCUSA-N IMP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-KQYNXXCUSA-N 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 235000012377 Salvia columbariae var. columbariae Nutrition 0.000 description 1
- 240000005481 Salvia hispanica Species 0.000 description 1
- 235000001498 Salvia hispanica Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 235000014167 chia Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- IQLUYYHUNSSHIY-HZUMYPAESA-N eicosatetraenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C(O)=O IQLUYYHUNSSHIY-HZUMYPAESA-N 0.000 description 1
- 238000004993 emission spectroscopy Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000021321 essential mineral Nutrition 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003778 fat substitute Substances 0.000 description 1
- 235000013341 fat substitute Nutrition 0.000 description 1
- 235000019387 fatty acid methyl ester Nutrition 0.000 description 1
- 230000001189 fecal softening effect Effects 0.000 description 1
- 235000004426 flaxseed Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 239000012520 frozen sample Substances 0.000 description 1
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 1
- -1 fructose oligosaccharide Chemical class 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 235000006486 human diet Nutrition 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- XKVWLLRDBHAWBL-UHFFFAOYSA-N imperatorin Natural products CC(=CCOc1c2OCCc2cc3C=CC(=O)Oc13)C XKVWLLRDBHAWBL-UHFFFAOYSA-N 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 229940033355 lauric acid Drugs 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229930003658 monoterpene Natural products 0.000 description 1
- 150000002773 monoterpene derivatives Chemical class 0.000 description 1
- 235000002577 monoterpenes Nutrition 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- PVNIQBQSYATKKL-UHFFFAOYSA-N tripalmitin Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1528—Fatty acids; Mono- or diglycerides; Petroleum jelly; Paraffine; Phospholipids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
- A23C9/203—Dietetic milk products not covered by groups A23C9/12 - A23C9/18 containing bifidus-active substances, e.g. lactulose; containing oligosaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/22—Comminuted fibrous parts of plants, e.g. bagasse or pulp
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Botany (AREA)
- Pediatric Medicine (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Dairy Products (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Detergent Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Edible Oils And Fats (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本發明提供一種具有相對高含量三酸甘油酯之嬰兒配方,該三酸甘油酯在sn-2位置處具有棕櫚酸。該配方可包括果寡糖。該配方亦可包括至少一種Ω6脂肪酸及至少一種Ω3脂肪酸。該配方亦可含有相對較低蛋白質含量及類似於母乳之α-乳白蛋白含量。本發明亦包括一種用以改善經以配方餵養嬰兒的糞便堅實度、增加結腸內雙歧桿菌及降低糞便中鈣皂之方法。
Description
本發明係關於嬰兒配方組合物,其含有高量sn-2棕櫚酸三甘油酯及果寡糖。
三酸甘油酯係由具有3個羥基之甘油與3個脂肪酸分子之間的酯鍵所形成。三酸甘油酯在能源來源的代謝作用中扮演著重要的角色。在腸內,三酸甘油酯在所稱為脂肪分解之過程中會***成單醯甘油及游離脂肪酸,其中游離脂肪酸係從三酸甘油酯之sn-1及sn-3位置處分離而來。不飽和游離脂肪酸被腸吸收比飽和脂肪酸容易得多。當三酸甘油酯sn-1及/或sn-3位置處包括高百分比之飽和脂肪酸殘基時,因脂肪分解所形成之游離脂肪酸(諸如棕櫚酸)會與礦物質(諸如鈣或鎂)結合而形成皂,致使糞便會較堅硬及更難以排出。此皂形成亦會干擾鈣的吸收。
母乳脂肪三酸甘油酯含有約20-25%棕櫚酸殘基,其中約70%存在於其所鍵結之甘油酯sn-2位置處。植物油通常用於替代嬰兒配方中乳脂。植物油三酸甘油酯典型地具有高百分比,典型地為80-85%或大於80-85%之存在於sn-1或sn-3位置處之棕櫚酸。因此,消化母乳期間所形成之游離脂肪酸主要為不飽和脂肪酸,而消化植物油期間所釋放之脂肪酸大部分為飽和脂肪酸,其可與鈣結合形成皂。此可解釋為何母乳餵養之嬰兒之糞便已知比配方餵養之嬰兒軟。
亞麻油酸(LA)(主要為Ω6脂肪酸)及α次亞麻油酸(ALA)(主要為Ω3脂肪酸)為人類正常生長及發育所必需的。LA及ALA脂肪酸代謝上截然不同,不能在人體內合成且必須由哺乳動物之飲食中獲得。在進化史期間,在人類飲食中關於LA與ALA之攝入存在大體平衡且LA:ALA之比率為約1比約1。由於現代農業方法及易於運輸,LA高量之植物油(玉米油、葵花油、紅花油、大豆油)食用增加,使許多哺乳動物飲食,尤其在西方社會中,LA:ALA哺乳動物攝入之比率自約1:1顯著變化成約10-25 LA比約1 ALA。
需要具有一種嬰兒配方,其中三酸甘油酯比植物油中所存在之三酸甘油酯具有更多sn-2棕櫚酸酯及更少sn-1與sn-3棕櫚酸酯。
在嬰兒配方中,需要使用β棕櫚酸酯脂肪使脂肪混合物最佳化以改良鈣增長且降低糞便皂脂肪酸。又,以約6比約1之比率包含至少一種Ω6脂肪酸及至少一種Ω3脂肪酸將提供短期及長期健康效益,包括改良的二十二碳六烯酸(「DHA」)生物可用性。
此項技術中已知具有此等特徵的多種植物源三酸甘油酯。
歐洲專利1237419描述一種嬰兒配方,其含有容易消化之脂質組分(其在甘油之sn-1及sn-3位置處不含高量飽和脂肪酸)、黏度改良組分、蛋白質組分(每100 g蛋白質含有小於0.75 g磷)及/或益生組分(諸如寡糖)。
WO 2005/036987描述一種新穎的基於脂肪之製劑,其包含具有多達38%棕櫚酸殘基之植物源三酸甘油酯之混合物,其中至少60%之棕櫚酸殘基在甘油酯之sn-2位置處,較佳地,其中sn-1及sn-3位置處由至少70%不飽和脂肪酸殘基(諸如油酸脂)佔據。
WO 2006/114791描述嬰兒配方之母乳脂替代品,其具有植物源三酸甘油酯,其中sn-2位置處之飽和脂肪酸殘基小於50%且/或sn-2位置處之飽和脂肪酸殘基小於總飽和脂肪酸殘基之43.5%。
果寡糖為具有相對較低聚合度之由果糖單元組成之寡糖。果寡糖在此項技術中熟知且可市購。
美國專利第7,651,716號揭示一種具有2.2-2.5 g/公升α-乳白蛋白(約0.3-0.4 g/100大卡)之嬰兒配方,且此配方類似於母乳。亦揭示嬰兒配方之總蛋白質含量為2.0-2.4 g/100大卡。
用於製造在sn-2位置處具有相對較高百分比之飽和脂肪殘基(諸如棕櫚酸)的三酸甘油酯組合物的方法描述於美國專利第5,658,768號、WO 2007/029015、WO 2007/029018、WO 2007/029020及WO 2008/104381中。Lipid Nutrition市售之組合物為BetapolTM B-55,其為衍生自植物油之三酸甘油酯混合物,其中甘油分子之sn-2位置處存在至少54%棕櫚酸。
本發明包含一種嬰兒配方,每100大卡嬰兒配方包含:
a)約5 g至約6 g脂肪,其中至少7.5 wt%總脂肪由棕櫚酸在sn-2位置處之三酸甘油酯組成;b)視情況存在之至少約0.4 g果寡糖;及,c)約1.8 g至約2.2 g總蛋白質,視情況包括約0.3 g至約0.4 g α-乳白蛋白。
本發明包含一種嬰兒配方,每100大卡嬰兒配方包含:a)約5-6 g脂肪,其中至少7.5 wt%總脂肪由棕櫚酸在sn-2位置處之三酸甘油酯組成;b)視情況存在之至少約0.4 g果寡糖;c)約1.8 g至約2.2 g總蛋白質,視情況包括約0.3 g至約0.4 g α-乳白蛋白;及,d.)比率為約6比約1之至少一種Ω6脂肪酸及至少一種Ω3脂肪酸。
本發明亦包含一種用於改良嬰兒之糞便堅實度的方法,其包含向該嬰兒投與本發明之嬰兒配方。
本發明進一步包含一種用於降低嬰兒糞便中鈣皂之量的方法,其包含向該嬰兒投與本發明之嬰兒配方。
本發明另外包含一種用於提高嬰兒結腸內之有益雙歧桿菌之量的方法。
本發明之其他重要態樣自以下說明將顯而易見。
如本文所用之術語「果寡糖」係指聚合度為2至10,例如聚合度為2至8之果糖寡聚物。
如本文所用之術語「sn-2棕櫚酸酯」係指鍵結於三酸甘
油酯之sn-2位置處的棕櫚酸。
如本文所用之術語「嬰兒配方」係指為嬰兒提供完全營養並適合餵養嬰兒,且滿足嬰兒配方之US或EU標準的營養配方(呈液體形式,或呈乾粉形式,此乾粉在添加水後可復原形成液體嬰兒配方)。該等配方熟知於此項技術中。
典型地,呈即食用(ready-to-consume)液體形式之嬰兒配方可提供60-70大卡/100 ml。每100大卡嬰兒配方典型地包含:約1.8-4.5 g蛋白質;約3.3-6.0 g脂肪(脂質);約300-1200 mg亞麻油酸;約9-14 g碳水化合物,其選自由以下組成之群:乳糖、蔗糖、葡萄糖、葡萄糖漿、澱粉、麥芽糊精及麥芽糖以及其組合;以及必需的維生素及礦物質。乳糖可為嬰兒配方中之主要碳水化合物。舉例而言,液體嬰兒配方可含有約67大卡/100 ml。在一些實施例中,嬰兒配方可包含約1.8-3.3 g蛋白質/100大卡。嬰兒配方可呈粉末形式,其可藉由添加一定量的水復原成即食餵養(ready-to-feed)液體,從而產生具有約67大卡/100 ml之液體。
嬰兒配方亦可包含選自以下之核苷酸:5'-單磷酸胞苷(CMP)、5'-單磷酸尿苷(UMP)、5'-單磷酸腺苷(AMP)、5'-單磷酸鳥苷(GMP)及5'-單磷酸肌苷(IMP)及其混合物。嬰兒配方亦可包含葉黃素、玉米黃素、果寡糖、半乳寡糖、唾液乳糖及/或海藻糖基乳糖。長鏈多元不飽和脂肪酸,諸如二十二碳六烯酸(DHA)及二十碳四烯酸(AA)可包括在嬰兒配方中。嬰兒配方亦可包括游離胺基酸。嬰兒配方亦
可包括此項技術中熟知之其他成分。
在一個實施例中,本發明嬰兒配方每100大卡包含約5-6 g脂肪(三酸甘油酯),其中至少約7.5 wt%(例如約7.5-12.0%)之脂肪係由三酸甘油酯sn-2位置處之棕櫚酸組成。在一些實施例中,約7.8-11.8%、約8.0-11.5 wt%、約8.5-11.0%或約9.0-10.0 wt%之脂肪為位於三酸甘油酯sn-2位置處之棕櫚酸。
在一些實施例中,棕櫚酸以重量計佔配方總脂肪酸含量約15%至約25%,諸如約15%至約20%,且總棕櫚酸含量至少約30%(例如約35%)至約43%係位於sn-2位置處。
在一些實施例中,嬰兒配方進一步包含比率為約6比約1之至少一種Ω6脂肪酸及至少一種Ω3脂肪酸。在一個實施例中,以重量計,至少一種Ω6脂肪佔總脂肪酸約10%至約15%且至少一種Ω3脂肪酸佔總脂肪酸之約1.2%至約3.6%。在一些實施例中,嬰兒配方包含以總重量約2%至約4%存在之至少一種Ω6脂肪酸及以總重量約0.3%至約0.6%存在之至少一種Ω3脂肪酸。
本發明嬰兒配方中之脂肪包含典型發現於牛奶及/或嬰兒配方中之多種三酸甘油酯。三酸甘油酯之最常見脂肪酸殘基為棕櫚酸及油酸。除油酸及棕櫚酸之外存在之脂肪酸殘基包括(但不限於)亞麻油酸、α次亞麻油酸、月桂酸、肉豆蔻酸、二十二碳六烯酸及二十碳四烯酸。
Lipid Nutrition市售之組合物為BetapolTM B-55,其為衍生自植物油之三酸甘油酯混合物,其中至少54%棕櫚酸位
於甘油分子sn-2位置處。在一個實施例中,本發明配方之脂肪含量為約40重量%-50重量% BetapolTM B-55,例如約43重量%至約45重量%。熟習此項技術者應瞭解,所用高量sn-2脂肪之百分比及配方中sn-2棕櫚酸酯之總量可變化,且在不背離本發明之精神及範疇的情況下可使用不同的高量sn-2棕櫚酸酯油。
雖然給嬰兒餵養含有高百分比sn-2棕櫚酸酯之配方有助於產生較軟糞便及結腸內雙歧桿菌之生長,但高量sn-2棕櫚酸酯與果寡糖之組合提供顯著優良的糞便軟化及配方餵養嬰兒結腸內雙歧桿菌之生長。亦可顯著降低潛在病原細菌之量。已發現給嬰兒餵養含有約3 g/公升至約5 g/公升或約0.4 g/100大卡至約0.7 g/100大卡之果寡糖的含高量sn-2棕櫚酸酯之嬰兒配方比給嬰兒餵養無果寡糖之相同配方更有益。
相較於標準嬰兒配方,本發明可減少糞便棕櫚酸皂,從而可減少便秘且改良胃腸耐受性。
本發明之嬰兒配方含有至少約0.4 g果寡糖/100大卡。在一些實施例中,其含有約0.4 g至約0.9 g、約0.4 g至約0.7 g、約0.4 g至約0.5 g、約0.7 g至約0.8 g或約0.7 g至約0.9 g果寡糖/100大卡。果寡糖之聚合度為2至10。在一個實施例中,至少90%之果寡糖的聚合度為2至8。
近來嬰兒臨床研究已顯示含有約6比約1比率之至少一種Ω6脂肪酸及至少一種Ω3脂肪酸的營養配方提高了紅血球及血漿中之DHA增長。Ω6脂肪酸相對於Ω3脂肪酸約6:1之
平衡比率亦可提供長期健康效益,包括預防心血管疾病。藉由具有Ω6脂肪酸含量(諸如大豆油及葵花油)及Ω3脂肪酸含量(例如油菜籽、芥花、亞麻籽、歐鼠尾草(chia)、蘇子(perlla)或胡桃)之植物油脂肪源調配本發明將達成此平衡。具有5種不同油之獨特的脂肪混合物將用於達成經改進之脂肪混合物。
在一個實施例中,本發明之嬰兒配方包含約1.8 g至約2.2 g總蛋白質/100大卡,例如約1.8 g至約2.1 g或約1.9 g至約2.1 g蛋白質/100大卡,其中約0.3 g/100大卡至約0.4 g/100大卡之蛋白質為α-乳白蛋白。本發明之嬰兒配方可呈即餵養液體形式或可為液體濃縮物或粉末配方,其可藉由添加一定量的水復原成即食餵養液體,從而產生具有約67大卡/100 ml之液體。本發明之嬰兒配方包括US或EU法律所需之所有成分,包括(但不限於)某些維生素、礦物質及必需胺基酸。其亦可包括核苷酸(諸如CMP、UMP、AMP、GMP及IMP)、葉黃素、玉米黃素及此項技術中已知之其他成分。
呈現以下實例以說明本發明之某些實施例及特徵,但不應理解為限制本發明之範疇。
1.對照配方
其係為即食餵養液體嬰兒配方,該對照配方具有670大卡/公升。成分顯示如下:
對照配方亦包括必需胺基酸、礦物質及微量元素、核苷酸以及視情況存在之各種成分及嬰兒配方中常用之食品添加劑。
2.高量sn-2配方
此配方與對照配方相同,除9.6 wt%脂肪為sn-2棕櫚酸酯之外。此藉由使用具有57%植物油及43% BetapolTM B-55之脂肪來達成,其中約55%棕櫚酸位於sn-2位置處。
3.高量sn-2+果寡糖配方A
此配方與高量sn-2配方相同,除包括3.0 g/公升(0.4 g/100大卡)果寡糖之外。
4.高量sn-2+果寡糖配方B
此配方與高量sn-2配方相同,除包括5.0 g/公升(0.7 g/100大卡)果寡糖之外。
5.高量sn-2+果寡糖+Ω6及Ω3配方C
此配方與高量sn-2配方相同,除配方C包括約3 g/L至約5 g/公升(約0.75 g/100大卡)果寡糖及約4.5公克/復原公升(RL)(約0.65 g/100大卡)Ω6脂肪酸及約730 mg/RL(110 mg/100大卡)Ω3脂肪酸之外。
以雙盲隨機對照設計進行研究,對三種嬰兒配方(高量
sn-2配方、高量sn-2+果寡糖配方A,及高量sn-2+果寡糖配方B)與對照配方進行比較。不測試配方C。亦包括人類母乳作為非隨機參考組。將300名配方餵養嬰兒隨機分成四組(每組75人),且用實例1之不同嬰兒配方(對照配方、高量sn-2配方、高量sn-2+果寡糖配方A或高量sn-2+果寡糖配方B)餵養各組持續八週。另一組75名嬰兒用人類母乳餵養8週。在研究開始時,所有嬰兒皆為7-14日齡的健康期嬰兒。
作為一種結果量度,在170名嬰兒之子組中,收集基線時及第8週訪問時之糞便樣品且使用螢光原位雜交(FISH)法分析糞便微生物菌叢。已明確,FISH為用於特異性且快速偵測未經培養之臨床樣品中之微生物的非常有價值的工具。嬰兒子組中糞便微生物菌叢之分析顯示,經高量sn-2棕櫚酸酯配方(添加有果寡糖(「SN2+OF」)或未添加果寡糖(「SN2」))餵養之嬰兒在第8週期間的糞便雙歧桿菌濃度相較於對照組顯著大幅增加(對於SN2組,p=0.033;對於SN2+OF組,p0.002),且與母乳(「HM」)餵養嬰兒無顯著差異,如圖1所示。此發現表明單獨高量sn-2棕櫚酸酯配方對有益雙歧桿菌之生長具有刺激效應,從而使消化系統中雙歧桿菌之量增加,與母乳餵養嬰兒之結腸內之天然含量極其相似。
為量測糞便生物化學組成,在第8週期間收集嬰兒糞便樣品,並分析以下糞便組成變數:個別皂脂肪酸;非皂脂肪酸;總脂肪酸;皂脂質;非皂脂質;礦物質:鈣、鎂、
及磷;氮;糞便固體及糞便水分。兩項最重要之糞便組成評估是棕櫚酸皂及總脂肪酸皂(在統計分析計畫中預先測定)。使用提供給父母/法定監護人之套組,在第8週最終訪問之前的5天時段期間,在家收集所有研究嬰兒之糞便樣品。給嬰兒穿上在嬰兒產生糞便(bowel movement)之區域含有一條防水透氣(Tegaderm)帶之尿布以幫助糞便停留在尿布中。父母在收集期間舀取新鮮排出的糞便,將樣品存放於琥珀色塑料袋中,以手提秤稱重每袋的重量,且將袋儲存於家用冰箱之冷凍區中。
一旦收集到至少30 g糞便,研究人員即將收集套組冷卻袋中之冷凍樣品轉移至研究診所且儲存在-20℃冷凍器中。樣品於乾冰上冷凍運送至Covance Laboratories,Inc.,Madison,Wisconsin,USA,使用Quinlan等人引述之方法分析樣品以測定總皂脂肪酸、非皂脂肪酸、總脂肪酸、皂脂質及非皂脂質。使用標準分析程序測定糞便水分及固體。包括鈣、磷及鎂之礦物質含量係藉由ICP發射光譜、利用國際公定分析化學家協會(AOAC International;AOAC)公定分析方法來測定。藉由杜馬斯法(Dumas Method)使用燃燒-偵測技術測定氮。
為測定皂脂肪酸及非皂脂肪酸,解凍糞便樣品,以攪拌方式加以均質化,且記錄濕糞便之重量。隨後凍乾樣品並記錄乾糞便重量。將0.5 g至1.0 g經冷凍乾燥的糞便樣品轉移至萃取套管中,且藉由溶劑回流萃取以獲得中性脂質,包括非皂游離脂肪酸。用乙酸處理套管中殘留之樣品以釋
放皂脂肪酸,其隨後藉由第二次溶劑回流步驟加以分離。將內標標準物添加至兩種萃取物中,而游離酸會被吸收至無水鹼***換樹脂上。隨後利用鹽酸及甲醇從樹脂萃取出游離酸並轉化成甲酯。藉由氣相層析分析所得脂肪酸甲酯。所關注的脂肪酸為:月桂酸(C12:0)、肉豆蔻酸(C14:0)、棕櫚酸(C16:0)、硬脂酸(C18:0)、油酸(C18:1)及亞麻油酸(C18:2)。由於所關注的主要脂肪酸為C16:0;因此對於分析,將定量限度(limit of quantitation;LOQ)定義成對應於0.05%之最低C16:0校正標準的樣品濃度,隨後針對將樣品重量加以調整。與品質對照(QC)樣品中先前確定之目標值相比,關於脂肪酸之回收率及變異係數(CV)的接受準則為+/- 30%,因為重複分析之效能與準確度有關。C16:0之乾燥品質對照物(QC)含量的重複性相對標準差(RSD)值為2.9%至12.6%。總皂脂肪酸以所有量測的個別皂脂肪酸之總和形式計算。總非皂脂肪酸以所有量測的個別非皂脂肪酸之總和形式計算。總脂肪酸以總非皂脂肪酸加總皂脂肪酸之形式計算。結果以每公克乾糞便重量之毫克數表示。
為量測糞便特徵(堅實度及頻率),父母/法定監護人完成連續三日之3日糞便日記,緊接著為第4週及第8週之研究訪問,其中父母/法定監護人基於代表性糞便之標準化圖像伴隨日記說明,記錄每天糞便次數及糞便堅實度,如1=鬆軟,2=軟而黏,3=軟糊狀,4=成形或5=堅硬。五個糞便堅實度選項係基於Weaver等人之經驗證之5點量表。
如圖2所示,餵養無果寡糖之高量sn-2棕櫚酸酯配方之嬰兒的成形糞便顯著少於對照組,且含有高量sn-2棕櫚酸酯及果寡糖之配方形成的糞便甚至更少,接近母乳組之含量。
所有高量sn-2棕櫚酸酯配方(具有及不具有果寡糖)產生的棕櫚酸皂之含量顯著低於對照配方,與母乳類似,如圖3所示。
對熟習此項技術者可想到本文未說明之本發明許多變化。本發明不限於本文所說明及所述之實施例,而是包含所附申請專利範圍範疇內之所有標的物。
圖1為顯示餵養各種嬰兒配方及母乳之嬰兒的糞便雙歧桿菌之變化的條形圖。
圖2為顯示餵養各種嬰兒配方及母乳之嬰兒的糞便堅實度之條形圖。
圖3為顯示餵養各種嬰兒配方及母乳之嬰兒的糞便中棕櫚酸皂之量的條形圖。
Claims (18)
- 一種嬰兒配方,每100大卡嬰兒配方中包含約5 g至約6 g脂肪,其中總脂肪之約7.5 wt%至約12.0 wt%係由sn-2位置處之棕櫚酸組成。
- 一種嬰兒配方,每100大卡嬰兒配方中包含:a)約5 g至約6 g脂肪,其中總脂肪之至少7.5 wt%係由sn-2位置處之棕櫚酸組成;b)至少約0.4 g果寡糖;及,c)約1.8 g至約2.2 g總蛋白質。
- 如請求項2之嬰兒配方,其中每100大卡中該蛋白質包含約0.3 g至約0.4 g之α-乳白蛋白。
- 如請求項3之嬰兒配方,其中每100大卡中該總蛋白質範圍約1.9 g至約2.1 g。
- 如請求項2至4中任一項之嬰兒配方,其中該總脂肪約7.5 wt%至約12.0 wt%係由sn-2位置處之棕櫚酸組成。
- 如請求項5之嬰兒配方,其中每100大卡嬰兒配方包含約0.4 g至約0.7 g果寡糖。
- 如請求項1之嬰兒配方,其中該總脂肪約7.8 wt%至約11.8 wt%係由sn-2位置處之棕櫚酸組成。
- 如請求項2至4及7中任一項之嬰兒配方,其中該脂肪中至少約30%之棕櫚酸係位於sn-2位置處。
- 如請求項2之嬰兒配方,其中:a)以100大卡計,該總蛋白質範圍約1.9 g至約2.1 g且包含約0.3 g之α-乳白蛋白; b)該總脂肪約7.5重量%至約12.0重量%係由sn-2位置處之棕櫚酸組成;c)該脂肪至少約30%之棕櫚酸係位於sn-2位置處;及,d)該配方每100大卡包含約0.4 g至約0.5 g果寡糖。
- 如請求項2之嬰兒配方,其中:a)以100大卡計,該總蛋白質範圍約1.9 g至約2.1 g且包含約0.3 g之α-乳白蛋白;b)該總脂肪約7.5重量%至約12.0重量%係由sn-2位置處之棕櫚酸組成;c)該脂肪至少約30%之棕櫚酸係位於sn-2位置處;及,d)該配方每100大卡包含約0.7 g至約0.8 g果寡糖。
- 如請求項2至4、7、9及10中任一項之嬰兒配方,其中該脂肪約35-43%之棕櫚酸係位於sn-2位置處。
- 如請求項2至4、7、9及10中任一項之嬰兒配方,其中至少約90%果寡糖之聚合度為2至8。
- 一種請求項1至12中任一項之嬰兒配方的用途,其用於製造用以改善嬰兒糞便堅實度的藥品。
- 一種請求項1至12中任一項之嬰兒配方的用途,其用於製造用以降低嬰兒糞便中鈣皂含量的藥品。
- 一種請求項1至12中任一項之嬰兒配方的用途,其用於製造用以提高嬰兒糞便中糞便雙歧桿菌濃度的藥品。
- 一種請求項1至12中任一項之嬰兒配方的用途,其用於 製造用以降低嬰兒結腸內之潛在病原細菌含量的藥品。
- 一種嬰兒配方,每100大卡嬰兒配方包含:a)約5 g至約6 g脂肪,其中總脂肪至少7.5 wt%係由sn-2位置處之棕櫚酸組成;b)至少約0.4 g果寡糖;c)約1.8 g至約2.2 g總蛋白質;及,d)比率為約6比約1之至少一種Ω6脂肪酸及至少一種Ω3脂肪酸。
- 一種嬰兒配方,每100大卡嬰兒配方包含:a)約5 g至約6 g脂肪,其中該總脂肪至少7.5 wt%係由在sn-2位置處具有棕櫚酸之三酸甘油酯組成;b)視情況存在至少約0.4 g果寡糖;c)約1.8 g至約2.2 g總蛋白質,視情況包括約0.3 g至約0.4 g之α-乳白蛋白;及,d)比率為約6比約1之至少一種Ω6脂肪酸及至少一種Ω3脂肪酸。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161557950P | 2011-11-10 | 2011-11-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW201325470A true TW201325470A (zh) | 2013-07-01 |
Family
ID=47351884
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW101141934A TW201325470A (zh) | 2011-11-10 | 2012-11-09 | 含有高量sn-2棕櫚酸酯及果寡糖之嬰兒配方 |
Country Status (12)
Country | Link |
---|---|
US (2) | US20130266684A1 (zh) |
EP (1) | EP2800480A2 (zh) |
CN (1) | CN103929980A (zh) |
AU (1) | AU2012335224B2 (zh) |
BR (1) | BR112014010953A2 (zh) |
CL (1) | CL2014001229A1 (zh) |
MX (1) | MX350870B (zh) |
MY (1) | MY167583A (zh) |
RU (1) | RU2592902C2 (zh) |
TW (1) | TW201325470A (zh) |
WO (1) | WO2013068879A2 (zh) |
ZA (1) | ZA201404233B (zh) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016053085A1 (en) | 2014-09-30 | 2016-04-07 | N.V. Nutricia | Composition comprising a uridine source and butyrate producing fibres for preventing gastrointestinal disorders |
WO2016097220A1 (en) * | 2014-12-19 | 2016-06-23 | Nestec S.A. | Infant nutrition with hydrolysed protein, ionic calcium and palmitic acid |
CN105028659B (zh) * | 2015-05-14 | 2018-10-30 | 江南大学 | 一种人乳替代脂组合物 |
WO2016207061A1 (en) * | 2015-06-23 | 2016-12-29 | Nestec S.A. | Nutritional compositions and infant formulas containing oligofructose for reducing the load of pathogenic bacteria in the guts of infants and young children |
US11399559B2 (en) | 2015-07-29 | 2022-08-02 | Abbott Laboratories | Nutritional products having improved lipophilic solubility and bioavailability in an easily mixable form |
ES2879985T3 (es) | 2015-08-04 | 2021-11-23 | Nestle Sa | Composiciones nutritivas y fórmulas infantiles que comprenden Bifidobacterium animalis ssp. lactis y, opcionalmente, una mezcla de oligosacáridos para inducir una microbiota intestinal cercana a la de bebés alimentados por lactancia materna |
CN107847509B (zh) * | 2015-08-04 | 2021-06-01 | 雀巢产品有限公司 | 具有2FL和LNnT的营养组合物 |
US20180368462A1 (en) * | 2015-12-18 | 2018-12-27 | Nestec S.A. | Nutritional compositions and infant formulas containing relatively high level of oligofructose for inducing gut microbiota patterns close to those of human milk fed infants |
US10039805B1 (en) | 2016-02-26 | 2018-08-07 | Michelle Ann Toothman | Infant formulas having vitamin complexes with enhanced bioavailability |
US10617700B1 (en) | 2016-02-26 | 2020-04-14 | Michelle Ann Toothman | Vitamin supplement compositions with enhanced bioavailability |
US11122833B1 (en) | 2016-02-26 | 2021-09-21 | Michelle Ann Toothman | Infant formulas having vitamin complexes with enhanced bioavailability |
BR112019001181A2 (pt) | 2016-08-05 | 2019-04-30 | Nestec S.A. | composição de lipídios para uso em bebês e crianças pequenas para promover conforto intestinal e ótima absorção de gordura e cálcio |
US11197917B2 (en) | 2017-12-01 | 2021-12-14 | ByHeart, Inc. | Formulations for nutritional support in subjects in need thereof |
CN112823646A (zh) * | 2019-11-20 | 2021-05-21 | 内蒙古伊利实业集团股份有限公司 | 组合物、食品或药品及其用途 |
CN111345351A (zh) * | 2020-04-20 | 2020-06-30 | 临夏州燎原乳业有限公司 | 一种新型奶粉以及制造方法 |
WO2022078679A1 (en) | 2020-10-13 | 2022-04-21 | Frieslandcampina Nederland B.V. | Nutritional composition |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE154826T1 (de) | 1993-05-13 | 1997-07-15 | Loders Croklaan Bv | Verfahren zur herstellung von muttermilch - fettersatzstoffen |
US5827526A (en) * | 1995-07-11 | 1998-10-27 | Abbott Laboratories | Use of indigestible oligosaccharides to prevent gastrointestinal infections and reduce duration of diarrhea in humans |
EP1062873A1 (en) * | 1999-12-13 | 2000-12-27 | N.V. Nutricia | Improved infant formula, protein hydrolysate for use in such an infant formula, and method for producing such a hydrolysate |
US6913778B2 (en) * | 2001-12-21 | 2005-07-05 | Wyeth | Infant formula compositions comprising increased amounts of alpha-lactalbumin |
US7651716B2 (en) | 2001-12-21 | 2010-01-26 | Wyeth Llc | Methods for reducing adverse effects of feeding formula to infants |
IL158555A0 (en) | 2003-10-22 | 2004-05-12 | Enzymotec Ltd | Human breast milk lipid mimetic as dietary supplement |
KR101368603B1 (ko) | 2005-04-27 | 2014-02-27 | 엔지모테크 리미티드 | 모유 지방 대체물 |
KR101126305B1 (ko) | 2005-09-08 | 2012-03-19 | 로더스 크로클란 비.브이. | 디올레오일 팔미토일 글리세리드 제조 방법 |
EP1928988B1 (en) | 2005-09-08 | 2011-11-09 | Loders Croklaan B.V. | Triglyceride process |
EP1928989B1 (en) | 2005-09-08 | 2011-11-09 | Loders Croklaan B.V. | Process for producing triglycerides |
JP2009533064A (ja) * | 2006-04-11 | 2009-09-17 | マーテック バイオサイエンシーズ コーポレーション | 長鎖多価不飽和脂肪酸を含む食品製品、およびそれらを調製するための方法 |
US20080003329A1 (en) * | 2006-06-30 | 2008-01-03 | Ricardo Rueda | Enriched infant formulas |
DK2115107T3 (en) | 2007-02-28 | 2018-06-18 | Loders Croklaan Bv | PROCEDURE FOR PREPARING A GLYCERIDE COMPOSITION |
IL184982A0 (en) * | 2007-08-01 | 2008-01-20 | Enzymotec Ltd | Edible fat composition for enhancing bone strength |
US20090131523A1 (en) * | 2007-10-15 | 2009-05-21 | Enzymotec Ltd. | Lipid compositions for the treatment and prevention of proliferative diseases and for the reduction of incidences of mutagenesis and carinogenesis |
US7770966B2 (en) * | 2007-11-12 | 2010-08-10 | Be Aerospace, Inc. | Convertible passenger seat assembly |
DK2563167T3 (en) * | 2010-04-26 | 2015-05-18 | Enzymotec Ltd | PRACTICES AND lipid TO PROMOTE DEVELOPMENT OF INTESTINAL FLORA |
-
2012
- 2012-10-29 MY MYPI2014701195A patent/MY167583A/en unknown
- 2012-10-29 AU AU2012335224A patent/AU2012335224B2/en active Active
- 2012-10-29 CN CN201280055439.3A patent/CN103929980A/zh active Pending
- 2012-10-29 EP EP12799298.0A patent/EP2800480A2/en not_active Withdrawn
- 2012-10-29 BR BR112014010953A patent/BR112014010953A2/pt not_active IP Right Cessation
- 2012-10-29 RU RU2014123509/13A patent/RU2592902C2/ru active
- 2012-10-29 WO PCT/IB2012/055975 patent/WO2013068879A2/en active Application Filing
- 2012-10-29 MX MX2014005628A patent/MX350870B/es active IP Right Grant
- 2012-11-02 US US13/667,765 patent/US20130266684A1/en not_active Abandoned
- 2012-11-09 TW TW101141934A patent/TW201325470A/zh unknown
-
2013
- 2013-10-29 US US14/357,625 patent/US20140323574A1/en not_active Abandoned
-
2014
- 2014-05-09 CL CL2014001229A patent/CL2014001229A1/es unknown
- 2014-06-09 ZA ZA2014/04233A patent/ZA201404233B/en unknown
Also Published As
Publication number | Publication date |
---|---|
RU2014123509A (ru) | 2015-12-20 |
AU2012335224A1 (en) | 2014-04-24 |
WO2013068879A2 (en) | 2013-05-16 |
BR112014010953A2 (pt) | 2017-12-05 |
RU2592902C2 (ru) | 2016-07-27 |
EP2800480A2 (en) | 2014-11-12 |
WO2013068879A3 (en) | 2013-07-11 |
ZA201404233B (en) | 2019-04-24 |
MY167583A (en) | 2018-09-20 |
AU2012335224B2 (en) | 2016-10-13 |
MX350870B (es) | 2017-09-22 |
US20140323574A1 (en) | 2014-10-30 |
CN103929980A (zh) | 2014-07-16 |
MX2014005628A (es) | 2014-10-17 |
US20130266684A1 (en) | 2013-10-10 |
CL2014001229A1 (es) | 2014-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW201325470A (zh) | 含有高量sn-2棕櫚酸酯及果寡糖之嬰兒配方 | |
JP5954634B2 (ja) | 腸管内菌叢の発達を促進する方法及び脂質組成物 | |
AU2014253404B2 (en) | Infant formula with a low content of MCFAs in specific proportions and a relatively high content of unsaturated fatty acids, and its use in promoting the healthy establishment of cognitive function in infants | |
CN103260440A (zh) | 包括含有甘油单酯的新脂肪***的营养型产品 | |
CN103781370A (zh) | 用于调节生命后期食物摄入的婴儿营养物 | |
TW201010623A (en) | Nutritional compositions containing punicalagins | |
CN105120687B (zh) | 具有特定比率的低含量中链脂肪酸的婴儿配方乳及其在促进和/或保证婴儿平衡生长方面的用途 | |
RU2695699C2 (ru) | Питательная композиция с низким содержанием среднецепочечных жирных кислот в определенных соотношениях и ее применение | |
WO2002094039A1 (en) | Food or beverage for ameliorating poor protein/energy nutrition | |
TWI669115B (zh) | Antiallergic agent, allergic diarrhea improving agent and pharmaceutical composition | |
JP4307475B2 (ja) | 乳幼児用栄養組成物 | |
IL261544A (en) | Lipid preparations and their uses |